Accessibility Menu
Abivax Société Anonyme logo

Abivax Société Anonyme(NASDAQ) ABVX

Market Cap$10.37BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2023)+1,332%
5 YearN/A
1 Year+70%
1 Month+24%
$124.37
+4.65%
+5.53Today
Abivax Société Anonyme last closing stock price
MetricPriceDate
Last closeUSD 118.842026-07-29
Abivax Société Anonyme stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-8.39%USD 129.732026-07-22
1 month+23.6%USD 96.152026-06-29
3 month+1.24%USD 117.382026-04-30
Year to date-11.88%USD 134.862025-12-31
1 year+70.26%USD 69.802025-07-29
Since inception+1,331.81%USD 8.302023-10-20

Abivax Société Anonyme Financials at a Glance

Market Cap

$10.37BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€0.00

Net Income (TTM)

-€427.24M

EPS (TTM)

-$5.25

P/E Ratio

-22.62

Dividend

$0.00

Beta (Volatility)

0.88 (Low)

Price

$124.37

Volume

1,493,059.38

Open

$119.60

Previous Close

$124.33

Daily Range

$119.00 - $125.39

52-Week Range

$67.09 - $148.83

Estimated Earnings Date

Sep 21, 2026

ABVX News

Person raising two fists in the air.

3 Soaring Stocks That May Have More Upside Ahead

Prosper Junior BakinyJul 7, 2026
research scientists drugs pharma biotech

This Stock Is Up 1,000% Over the Past Year. Is There More Upside Ahead?

Prosper Junior BakinyJun 3, 2026
Abivax and Viking Therapeutics logos

2 Stocks That Could Realistically Double by 2030

Prosper Junior BakinyMay 22, 2026
research scientists drugs pharma biotech

This Beaten-Down Drug Stock Is Down Over 10% -- Is It Finally a Buy?

Prosper Junior BakinyApr 7, 2026
alphataumedical

2 Healthcare Stocks to Buy Before They Get Bought Out

James HalleyMar 20, 2026
Person raising two fists in the air.

Billionaire Steve Cohen Owns Shares of This Stock That Has Soared 1,600% in The Past Year

Prosper Junior BakinyMar 10, 2026
research scientists drugs pharma biotech

2 Reasons Abivax Stock Could 10X by 2036

Prosper Junior BakinyFeb 27, 2026
Person raising two fists in the air.

Prediction: This Healthcare Stock Could Soar by 72% in 2026

Prosper Junior BakinyJan 19, 2026
Page 1

ABVX: Motley Fool Moneyball Superscore

57

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Abivax Société Anonyme

Abivax S.A. is a French pharmaceutical company dedicated to the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. The company is advancing its lead product, ABX464, through various clinical trials, targeting conditions such as ulcerative colitis, Crohn's Disease, and COVID-19.

Products and Services
  • ABX464: A therapeutic candidate in Phase IIb trials for ulcerative colitis and Crohn's Disease
  • ABX196: An immune-boosting candidate in Phase 1/2 trials for hepatocellular cancer
  • Research initiatives for diseases like Dengue fever and respiratory syncytial virus
Growth Outlook
  • ABX464 shows promise in multiple indications, enhancing market potential
  • Strong partnerships with leading French scientific institutions bolster research capabilities
  • Expansion into new therapeutic areas may drive future revenue growth
Financial Highlights
  • Recent quarterly revenue of 2,326,000 EUR, indicating ongoing operational activity
  • Cash and cash equivalents of 516,465,096 EUR provide a solid financial foundation
  • Current ratio of 8.75 suggests strong liquidity and financial health
AI Generated • Jul 19, 2026

Industry

Biotechnology

Sector

Health Care

Employees

69

CEO

Marc M. P. de Garidel, EMBA

Website

www.abivax.com

Headquarters

Paris, IF 75008, FR

ABVX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-165.19%

Return on Capital

-49.12%

Return on Assets

-57.52%

Earnings Yield

-4.42%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$10.37BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

87.25M

Volume

1.49M

Avg. Volume

2.08M

Financials (TTM)

Gross Profit

€0.00

Operating Income

-€328.58M

EBITDA

-€382.84M

Operating Cash Flow

-€249.39M

Capital Expenditure

-€375.00K

Free Cash Flow

-€249.96M

Cash & ST Invst.

€530.16M

Total Debt

€45.89M

Abivax Société Anonyme Performance Analysis

Abivax Société Anonyme annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 0N/A
20232023-12-31EUR 0N/A
20242024-12-31EUR 0N/A
20252025-12-31EUR 0N/A
Abivax Société Anonyme sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30-100.0%
Q42024-12-31N/A
Q22025-06-30N/A
Q42025-12-31N/A
Abivax Société Anonyme annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR -3.3414.6%
20232023-12-31EUR -3.7110.9%
20242024-12-31EUR -3.02-18.5%
20252025-12-31EUR -5.4680.4%
Abivax Société Anonyme sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-3067.2%
Q42024-12-31-130.8%
Q22025-06-30-6.0%
Q42025-12-31-32.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

€0.00

-100.0%

Gross Profit

€0.00

-100.0%

Gross Margin

0.00%

N/A

Market Cap

$10.37BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$129.62M

N/A

Employees

80

N/A

Net Income

-€287.69M

-200.3%

EBITDA

-€256.06M

-178.1%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

€530.16M

+103.1%

Total Debt

€45.89M

-20.9%

Accounts Receivable

€10.49M

-45.1%

Inventory

€0.00

N/A

Long Term Debt

€16.43M

-38.7%

Short Term Debt

€29.40M

-6.0%

Return on Assets

-57.52%

N/A

Return on Invested Capital

-48.08%

N/A

Free Cash Flow

-€71.28M

+0.0%

Operating Cash Flow

-€71.28M

-0.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CYTKCytokinetics, Incorporated
$80.42+2.60%
HALOHalozyme Therapeutics, Inc.
$83.30+0.02%
MDGLMadrigal Pharmaceuticals, Inc.
$493.11-9.83%
NUVLNuvalent, Inc.
$123.96+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$91.13+0.11%
NVDANvidia
$195.04+0.03%
MSFTMicrosoft
$451.10+0.16%
NOKNokia
$9.09+0.08%

Questions About ABVX

What is the current price of Abivax Société Anonyme?

Abivax Société Anonyme is trading at $124.33 per share.

What is the 52-week range for Abivax Société Anonyme?

Over the past 52 weeks, Abivax Société Anonyme has traded between $67.09 and $148.83.

How much debt does Abivax Société Anonyme have?

As of the most recent reporting period, Abivax Société Anonyme reported total debt of €39.42M.

How much cash does Abivax Société Anonyme have on hand?

Abivax Société Anonyme reported €550.09M in cash and cash equivalents in its most recent financial results.

What is Abivax Société Anonyme’s dividend yield?

Abivax Société Anonyme does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services